Introduction
On Monday, Intec Pharma (NTEC) announced their phase 3 trial assessing their proprietary Accordion Pill-Carbidopa/Levodopa for Parkinson's disease did not prove superior to immediate-release Carbidopa/Levodopa (Sinemet).
We are disappointed that the ACCORDANCE study didn't meet its target endpoints with statistical significance. While the data suggests that the AP CD/LD did achieve an acceptable safety profile and did treat Parkinson's disease symptoms, it did not achieve a statistically significant superiority to standard immediate release levodopa therapy. We are pleased with the good safety profile of the AP-CD/LD, as it demonstrates for the first